LPA2 receptor (lpar2_human)

FAMILY

Class A (Rhodopsin) Lipid receptors Lysophospholipid (LPA) receptors LPA2 receptor

GENE

LPAR2 (EDG4, LPA2)

ORGANISM

Human (Homo sapiens)

ALT. NAMES

Lysophosphatidic acid receptor 2, LPA receptor 2, LPA-2, Lysophosphatidic acid receptor Edg-4

SOURCE

SWISSPROT

SEQUENCE

N-term        
M
G
Q
C
Y
Y
N
E
T
I
10
                   
G
F
F
Y
N
N
S
G
K
E
20
            TM1  
L
S
S
H
W
R
P
K
D
V
30
                   
V
V
V
A
L
G
L
T
V
S
40
                   
V
L
V
L
L
T
N
L
L
V
50
                   
I
A
A
I
A
S
N
R
R
F
60
ICL1 TM2      
H
Q
P
I
Y
Y
L
L
G
N
70
                   
L
A
A
A
D
L
F
A
G
V
80
                   
A
Y
L
F
L
M
F
H
T
G
90
ECL1     TM3  
P
R
T
A
R
L
S
L
E
G
100
                   
W
F
L
R
Q
G
L
L
D
T
110
                   
S
L
T
A
S
V
A
T
L
L
120
                   
A
I
A
V
E
R
H
R
S
V
130
    ICL2        
M
A
V
Q
L
H
S
R
L
P
140
TM4              
R
G
R
V
V
M
L
I
V
G
150
                   
V
W
V
A
A
L
G
L
G
L
160
          ECL2  
L
P
A
H
S
W
H
C
L
C
170
                   
A
L
D
R
C
S
R
M
A
P
180
    TM5          
L
L
S
R
S
Y
L
A
V
W
190
                   
A
L
S
S
L
L
V
F
L
L
200
                   
M
V
A
V
Y
T
R
I
F
F
210
                   
Y
V
R
R
R
V
Q
R
M
A
220
ICL3 TM6      
E
H
V
S
C
H
P
R
Y
R
230
                   
E
T
T
L
S
L
V
K
T
V
240
                   
V
I
I
L
G
A
F
V
V
C
250
                   
W
T
P
G
Q
V
V
L
L
L
260
        ECL3    
D
G
L
G
C
E
S
C
N
V
270
TM7              
L
A
V
E
K
Y
F
L
L
L
280
                   
A
E
A
N
S
L
V
N
A
A
290
          H8      
V
Y
S
C
R
D
A
E
M
R
300
                   
R
T
F
R
R
L
L
C
C
A
310
C-term        
C
L
R
Q
S
T
R
E
S
V
320
                   
H
Y
T
S
S
A
Q
G
G
A
330
                   
S
T
R
I
M
L
P
E
N
G
340
               
H
P
L
M
D
S
T
L

LINKS

ChEMBL

Guide To Pharmacology

UniProt

DIAGRAMS

ICL1 R R F H ICL1ECL1 T G P R T A R L ECL1ICL2 V Q L H S R L ICL2ECL2 W H C L C A L D R C S R M A P L L ECL2ICL3 E H V S ICL3ECL3 C E S C ECL3N-term M G Q C Y Y N E T I G F F Y N N S G K E L S S H W R N-termC-term C A C L R Q S T R E S V H Y T S S A Q G G A S T R I M L P E N G H P L M D S T L C-term P K D V V V V A L G L T V S V L V L L T N L L V I A A I A S N Q P I Y Y L L G N L A A A D L F A G V A Y L F L M F H S L E G W F L R Q G L L D T S L T A S V A T L L A I A V E R H R S V M A P R G R V V M L I V G V W V A A L G L G L L P A H S S R S Y L A V W A L S S L L V F L L M V A V Y T R I F F Y V R R R V Q R M A C H P R Y R E T T L S L V K T V V I I L G A F V V C W T P G Q V V L L L D G L G N V L A V E K Y F L L L A E A N S L V N A A V Y S C R D A E F R R M R R T L L C
Pick color:
 
 
 
 
 
 
 
 
 
 
 
 




Invitro Mutant Data: Increased binding/potency: >5-fold, >10-fold; Reduced binding/potency: >5-fold, >10-fold; No/low effect (<5-fold); and N/A

L N T L L V L V S V T L G L A V V V V D 1 G N L A A A D L F A G V A Y L F L M F H 2 A L L T A V S A T L S T D L L G Q R L F 3 V V M L I V G V W V A A L G L G L L P A 4 Y V A V M L L F V L L S S L A W V A L Y 5 V I I L G A F V V C W T P G Q V V L L L 6 A A N V L S N A E A L L L F Y K E V A 7
Pick color:
 
 
 
 
 
 
 
 
 
 
 
 




Invitro Mutant Data: Increased binding/potency: >5-fold, >10-fold; Reduced binding/potency: >5-fold, >10-fold; No/low effect (<5-fold); and N/A

MUTATIONS

0 mutation data points available.

PHYSIOLOGICAL LIGANDS

farnesyl diphosphate, farnesyl monophosphate, 1-O-Oleoyl-D-glycerol 3-phosphoric acid, LPA, LYSOPHOSPHATIDIC ACID

STRUCTURE MODELS

lpar2_human active,

lpar2_human inactive

STRUCTURES

No structures available